Anti-Amyloid Precursor Protein antibody, prediluted (ab15273)


  • Product nameAnti-Amyloid Precursor Protein antibody, prediluted
    See all Amyloid Precursor Protein primary antibodies
  • Description
    Rabbit polyclonal to Amyloid Precursor Protein, prediluted
  • SpecificityAb15273 recognizes APP (beta-APP770) and is predicted to recognize beta-APP695 and beta-APP751. The antibody stains both cytoplasmic and extracellular areas.
  • Tested applicationsICC/IF, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic peptide (Human) (N terminal).

  • Positive control
    • Human brain of Alzheimers disease



Our Abpromise guarantee covers the use of ab15273 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesIHC-P: Working dilution, ready-to-use for 10 minutes at RT. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0 for 10 minutes followed by cooling at RT for 20 minutes.
    ICC/IF: See Abreview.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionFunctions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.
      Beta-amyloid peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Beta-amyloid 42 is a more effective reductant than beta-amyloid 40. Beta-amyloid peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. Beta-APP42 may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with Also bind GPC1 in lipid rafts.
      Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain.
      The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.
      N-APP binds TNFRSF21 triggering caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6).
    • Tissue specificityExpressed in all fetal tissues examined with highest levels in brain, kidney, heart and spleen. Weak expression in liver. In adult brain, highest expression found in the frontal lobe of the cortex and in the anterior perisylvian cortex-opercular gyri. Moderate expression in the cerebellar cortex, the posterior perisylvian cortex-opercular gyri and the temporal associated cortex. Weak expression found in the striate, extra-striate and motor cortices. Expressed in cerebrospinal fluid, and plasma. Isoform APP695 is the predominant form in neuronal tissue, isoform APP751 and isoform APP770 are widely expressed in non-neuronal cells. Isoform APP751 is the most abundant form in T-lymphocytes. Appican is expressed in astrocytes.
    • Involvement in diseaseAlzheimer disease 1
      Cerebral amyloid angiopathy, APP-related
    • Sequence similaritiesBelongs to the APP family.
      Contains 1 BPTI/Kunitz inhibitor domain.
    • DomainThe basolateral sorting signal (BaSS) is required for sorting of membrane proteins to the basolateral surface of epithelial cells.
      The NPXY sequence motif found in many tyrosine-phosphorylated proteins is required for the specific binding of the PID domain. However, additional amino acids either N- or C-terminal to the NPXY motif are often required for complete interaction. The PID domain-containing proteins which bind APP require the YENPTY motif for full interaction. These interactions are independent of phosphorylation on the terminal tyrosine residue. The NPXY site is also involved in clathrin-mediated endocytosis.
    • Post-translational
      Proteolytically processed under normal cellular conditions. Cleavage either by alpha-secretase, beta-secretase or theta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, and the retention of corresponding membrane-anchored C-terminal fragments, C80, C83 and C99. Subsequent processing of C80 and C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is non-amyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59). Many other minor beta-amyloid peptides, beta-amyloid 1-X peptides, are found in cerebral spinal fluid (CSF) including the beta-amyloid X-15 peptides, produced from the cleavage by alpha-secretase and all terminatiing at Gln-686.
      Proteolytically cleaved by caspases during neuronal apoptosis. Cleavage at Asp-739 by either caspase-6, -8 or -9 results in the production of the neurotoxic C31 peptide and the increased production of beta-amyloid peptides.
      N- and O-glycosylated. O-glycosylation on Ser and Thr residues with core 1 or possibly core 8 glycans. Partial tyrosine glycosylation (Tyr-681) is found on some minor, short beta-amyloid peptides (beta-amyloid 1-15, 1-16, 1-17, 1-18, 1-19 and 1-20) but not found on beta-amyloid 38, beta-amyloid 40 nor on beta-amyloid 42. Modification on a tyrosine is unusual and is more prevelant in AD patients. Glycans had Neu5AcHex(Neu5Ac)HexNAc-O-Tyr, Neu5AcNeu5AcHex(Neu5Ac)HexNAc-O-Tyr and O-AcNeu5AcNeu5AcHex(Neu5Ac)HexNAc-O-Tyr structures, where O-Ac is O-acetylation of Neu5Ac. Neu5AcNeu5Ac is most likely Neu5Ac 2,8Neu5Ac linked. O-glycosylations in the vicinity of the cleavage sites may influence the proteolytic processing. Appicans are L-APP isoforms with O-linked chondroitin sulfate.
      Phosphorylation in the C-terminal on tyrosine, threonine and serine residues is neuron-specific. Phosphorylation can affect APP processing, neuronal differentiation and interaction with other proteins. Phosphorylated on Thr-743 in neuronal cells by Cdc5 kinase and Mapk10, in dividing cells by Cdc2 kinase in a cell-cycle dependent manner with maximal levels at the G2/M phase and, in vitro, by GSK-3-beta. The Thr-743 phosphorylated form causes a conformational change which reduces binding of Fe65 family members. Phosphorylation on Tyr-757 is required for SHC binding. Phosphorylated in the extracellular domain by casein kinases on both soluble and membrane-bound APP. This phosphorylation is inhibited by heparin.
      Extracellular binding and reduction of copper, results in a corresponding oxidation of Cys-144 and Cys-158, and the formation of a disulfide bond. In vitro, the APP-Cu(+) complex in the presence of hydrogen peroxide results in an increased production of beta-amyloid-containing peptides.
      Trophic-factor deprivation triggers the cleavage of surface APP by beta-secretase to release sAPP-beta which is further cleaved to release an N-terminal fragment of APP (N-APP).
      Beta-amyloid peptides are degraded by IDE.
    • Cellular localizationMembrane. Membrane, clathrin-coated pit. Cell surface protein that rapidly becomes internalized via clathrin-coated pits. During maturation, the immature APP (N-glycosylated in the endoplasmic reticulum) moves to the Golgi complex where complete maturation occurs (O-glycosylated and sulfated). After alpha-secretase cleavage, soluble APP is released into the extracellular space and the C-terminal is internalized to endosomes and lysosomes. Some APP accumulates in secretory transport vesicles leaving the late Golgi compartment and returns to the cell surface. Gamma-CTF(59) peptide is located to both the cytoplasm and nuclei of neurons. It can be translocated to the nucleus through association with APBB1 (Fe65). Beta-APP42 associates with FRPL1 at the cell surface and the complex is then rapidly internalized. APP sorts to the basolateral surface in epithelial cells. During neuronal differentiation, the Thr-743 phosphorylated form is located mainly in growth cones, moderately in neurites and sparingly in the cell body. Casein kinase phosphorylation can occur either at the cell surface or within a post-Golgi compartment. Associates with GPC1 in perinuclear compartments. Colocalizes with SORL1 in a vesicular pattern in cytoplasm and perinuclear regions.
    • Information by UniProt
    • Database links
    • Alternative names
      • A4 amyloid protein antibody
      • A4 antibody
      • A4_HUMAN antibody
      • AAA antibody
      • ABETA antibody
      • ABPP antibody
      • AD 1 antibody
      • AD1 antibody
      • AICD-50 antibody
      • AICD-57 antibody
      • AICD-59 antibody
      • AID(50) antibody
      • AID(57) antibody
      • AID(59) antibody
      • Alzheimer disease 1 antibody
      • Alzheimer disease amyloid protein antibody
      • Alzheimer disease antibody
      • Alzheimer's disease amyloid protein antibody
      • Amyloid beta (A4) precursor protein antibody
      • Amyloid beta A4 protein antibody
      • Amyloid beta A4 protein precursor isoform b antibody
      • Amyloid beta A4 protein precursor isoform b antibody
      • Amyloid beta A4 protein precursor isoform c antibody
      • Amyloid beta A4 protein precursor isoform c antibody
      • Amyloid beta A4 protein precursor isoform a antibody
      • Amyloid beta A4 protein precursor isoform b antibody
      • Amyloid beta A4 protein precursor isoform b antibody
      • Amyloid beta A4 protein precursor isoform c antibody
      • Amyloid beta A4 protein precursor isoform c antibody
      • Amyloid beta protein antibody
      • Amyloid beta-peptide antibody
      • Amyloid intracellular domain 50 antibody
      • Amyloid intracellular domain 57 antibody
      • Amyloid intracellular domain 59 antibody
      • Amyloid of aging and alzheimer disease antibody
      • APP antibody
      • APP I antibody
      • APPI antibody
      • Beta amyloid peptide antibody
      • Beta-APP40 antibody
      • Beta-APP42 antibody
      • C31 antibody
      • Cerebral vascular amyloid peptide antibody
      • CTFgamma antibody
      • CVAP antibody
      • Gamma-CTF(50) antibody
      • Gamma-CTF(57) antibody
      • Gamma-CTF(59) antibody
      • Human mRNA for amyloid A4 precursor of Alzheimer's disease antibody
      • peptidase nexin II antibody
      • PN 2 antibody
      • PN II antibody
      • PN-II antibody
      • PN2 antibody
      • PreA4 antibody
      • Protease nexin II antibody
      • Protease nexin-II antibody
      • S-APP-alpha antibody
      • S-APP-beta antibody
      see all

    Anti-Amyloid Precursor Protein antibody, prediluted images

    • ab15273 used neat staining human brain with Alzheimer's disease by Immunohistochemistry.
    • ab15273 staining human HEK cells (transfected with swAPP-GFP) by immunocytochemistry. The antibody was added to living cells for 1 hour before the cells were fixed and bound antibody was detected with a goat anti-mouse IgG Alexa-Fluor 568 ® antibody. In the confocal image ab15273 recognises the N-term extracellular portion of the APP at the membrane as well as internal pools of APP. The GFP was attached to the APP at the C-terminus.

      This image is corutesy of an Abreview submitted by Randal Moldrich on 22 February 2006.

      See Abreview

    References for Anti-Amyloid Precursor Protein antibody, prediluted (ab15273)

    ab15273 has not yet been referenced specifically in any publications.

    Product Wall

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Immunocytochemistry/ Immunofluorescence
    Sample Human Cell (HEK cells)
    Specification HEK cells
    Fixative Paraformaldehyde
    Blocking step BSA as blocking agent for 40 minute(s) · Concentration: 5%

    Dr. Randal Moldrich

    Verified customer

    Submitted Apr 02 2007

    Thank you for your enquiry. The immunogen sequence used for ab15273 and ab15272 is as follows: HMNVQNGKWDSDPSGTKTC Please contact us again if you have any additional questions.